Cancers最新文献

{"title":"Multidisciplinary Tumor Board Evaluation of Pediatric Patients with Adrenocortical Tumors Across Seven International Centers.","authors":"Maria Riedmeier, Wiebke Schlötelburg, Shipra Agarwal, Ahitagni Biswas, Saniye Ekinci, Martin Fassnacht, Maria C B Villares Fragoso, E Nazli Gonc, Melis Gultekin, Mithat Haliloglu, Vishesh Jain, Manisha Jana, Dominika Janus, Jagdish Prasad Meena, Jessica Munarin, Diclehan Orhan, Jaydira Del Rivero, Rajni Sharma, Gerdi Tuli, Bilgehan Yalcin, Verena Wiegering","doi":"10.3390/cancers17061014","DOIUrl":"10.3390/cancers17061014","url":null,"abstract":"<p><strong>Background: </strong>The management of rare tumors at reference centers with specialized multidisciplinary tumor boards (MTBs) improves patient survival. No international standardized diagnostic and treatment recommendations for pediatric patients with adrenocortical carcinoma (ACC) exist so far. The aim of this case-based study is to determine how congruent treatment recommendations are in different specialized institutions in different countries.</p><p><strong>Methods: </strong>In this cross-sectional, case-based survey study, five anonymized patient cases, including imaging data of pediatric adrenocortical carcinomas (pACCs), were distributed to seven international specialized centers located in Brazil, Germany, India, Italy, Poland, Turkey, and the USA. The centers were tasked with providing recommendations regarding the treatment sequence and modalities, as well as indicating the level of consensus on these decisions within their MTBs. For each case, the treatment approach recommended by the highest number of centers was recorded to calculate an agreement percentage relative to all treatment recommendations made. The consensus level for each case was determined on a scale of 1 to 10, with higher scores indicating greater agreement among MTB members.</p><p><strong>Results: </strong>A total of five patient cases were discussed across seven MTBs, yielding a total of 34 treatment recommendations. The agreement percentages for the primary therapeutic approach for each case were as follows: primary therapeutic approach: 88.6%; surgical approaches: 51.8%; and systemic chemotherapy recommendations: 53%.</p><p><strong>Conclusions: </strong>This study represents the first case-based analysis of international inter-center agreement on pediatric ACC management. Inter-center agreement regarding treatment allocation and sequencing was low, while the level of consensus within each MTB was high. These findings point to potentially significant and clinically relevant differences in treatment standards across centers, highlighting the need for international collaboration and standardized diagnostic and therapeutic recommendations, especially for rare tumors. Increased case-based exchanges between centers are essential to reduce the substantial discrepancies observed here and to further standardize the management of pediatric patients with ACC.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience with the Available Outpatient COVID-19 THErapies in Patients with canceR (CO.THER).","authors":"Angioletta Lasagna, Giulia Gambini, Catherine Klersy, Simone Figini, Sofia Marino, Paolo Sacchi, Paolo Pedrazzoli","doi":"10.3390/cancers17060999","DOIUrl":"10.3390/cancers17060999","url":null,"abstract":"<p><strong>Background/objectives: </strong>Cancer represents an important risk factor for acquiring severe acute respiratory syndrome by Coronavirus-2 (SARS-CoV-2) and subsequent hospitalization. The utility of early antiviral therapies, including their protective effect on long COVID outcomes, in cancer patients has not yet been clearly demonstrated. We conducted the CO.THER study (COVID-19 THErapies in patients with canceR) to address this knowledge gap.</p><p><strong>Methods: </strong>We designed an ambispective single-center cohort study. We collected clinical and oncological data from the hospital's electronic patient records at the start of COVID-19 therapy (T0), seven days after T0 (T1), two weeks after T0 (T2), one month after T0 (T3), three months after T0 (T4), six months after T0 (T5), and twelve months after T0 (T6). The primary endpoint of this ambispective single-center cohort study was the rate of hospitalization for COVID-19 disease within 14 days in cancer patients using anti-SARS-CoV-2 early therapies. The proportion of hospitalizations within 14 days (primary endpoint) was computed together with its exact binomial 95% confidence interval (95%CI).</p><p><strong>Results: </strong>131 patients' records (53M [40.5%], 78F, [59.5%]; median age 62.45, interquartile range [IQR] 56-71) were enrolled. As shown by the Kaplan-Meier hospitalization-free estimate, only three patients (2.1%) were hospitalized for a COVID-19 related cause within 14 days of starting early treatment (95%CI 0.5-6.6%). The cumulative survival probability beyond 12 months in hospitalization-free patients was 98% (95%CI 93-99%). Twelve patients (9.2%) reported another COVID-19 infection during the follow-up and they were all retreated with Nirmatrelvir-Ritonavir. The cumulative reinfection-free survival was 90% at 12 months (95%CI 83-95%). Further, 15 patients of the 123 evaluable at 3 months (median age 51 years, IQR 40-68) reported long COVID symptoms (12.2%, 95%CI 7.0-19.3%).</p><p><strong>Conclusions: </strong>Our data demonstrate a low rate of hospitalization and reassuring data on safety in this cohort of high-risk subjects.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum-Based Proteomic Approach to Identify Clinical Biomarkers of Radiation Exposure.","authors":"Emeshaw Damtew Zebene, Biagio Pucci, Rita Lombardi, Hagos Tesfay Medhin, Edom Seife, Elena Di Gennaro, Alfredo Budillon, Gurja Belay Woldemichael","doi":"10.3390/cancers17061010","DOIUrl":"10.3390/cancers17061010","url":null,"abstract":"<p><strong>Background: </strong>Ionizing radiation (IR) exposure poses a significant health risk due to its widespread use in medical diagnostics and therapeutic applications, necessitating rapid and effective biomarkers for assessment.</p><p><strong>Objective: </strong>The aim of this study is to identify the serum proteomic signature of IR exposure in patients undergoing radiotherapy (RT).</p><p><strong>Methods: </strong>Blood samples were obtained from eighteen patients with head and neck cancer (HNC) and five patients with rectal cancer before and immediately after they underwent curative intensity-modulated radiotherapy (IMRT). The comprehensive serum proteome was analyzed in individual samples using nanoHPLC-MS/MS.</p><p><strong>Results: </strong>Forty radiation-modulated proteins (RMPs), 24 upregulated and 16 downregulated, with a fold change ≥1.5 and <i>p</i>-value < 0.05 were identified. About 40% of the RMPs are involved in acute phase response, DNA repair, and inflammation; the key RMPs were <i>ADCY1</i>, <i>HGF</i>, <i>MCEMP1</i>, <i>CHD4</i>, <i>RECQL5</i>, <i>MSH6</i>, and <i>ZNF224.</i> Conclusions: This study identifies a panel of serum proteins that may reflect the radiation response, providing a valuable molecular fingerprint of IR exposure and paving the way for the development of sensitive and specific biomarkers for early detection and clinical management of IR-related injuries.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Programmed Cell Death Ligand as a Biomarker for Response to Immunotherapy: Contribution of Mass Spectrometry-Based Analysis.","authors":"Marco Agostini, Pietro Traldi, Mahmoud Hamdan","doi":"10.3390/cancers17061001","DOIUrl":"10.3390/cancers17061001","url":null,"abstract":"<p><p>Immune checkpoint inhibition is a major component in today's cancer immunotherapy. In recent years, the FDA has approved a number of immune checkpoint inhibitors (ICIs) for the treatment of melanoma, non-small-cell lung, breast and gastrointestinal cancers. These inhibitors, which target cytotoxic T-lymphocyte antigen-4, programmed cell death (PD-1), and programmed cell death ligand (PD-L1) checkpoints have assumed a leading role in immunotherapy. The same inhibitors exert significant antitumor effects by overcoming tumor cell immune evasion and reversing T-cell exhaustion. The initial impact of this therapy in cancer treatment was justly described as revolutionary, however, clinical as well as research data which followed demonstrated that these innovative drugs are costly, are associated with potentially severe adverse effects, and only benefit a small subset of patients. These limitations encouraged enhanced research and clinical efforts to identify predictive biomarkers to stratify patients who are most likely to benefit from this form of therapy. The discovery and characterization of this class of biomarkers is pivotal in guiding individualized treatment against various forms of cancer. Currently, there are three FDA-approved predictive biomarkers, however, none of which on its own can deliver a reliable and precise response to immune therapy. Present literature identifies the absence of precise predictive biomarkers and poor understanding of the mechanisms behind tumor resistance as the main obstacles facing ICIs immunotherapy. In the present text, we discuss the dual role of PD-L1 as a biomarker for response to immunotherapy and as an immune checkpoint. The contribution of mass spectrometry-based analysis, particularly the impact of protein post-translational modifications on the performance of this protein is underlined.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rising Trends in Prostate Cancer Among Asian Men: Global Concerns and Diagnostic Solutions.","authors":"Li-Chuan Ko, Nick Gravina, Joos Berghausen, Joe Abdo","doi":"10.3390/cancers17061013","DOIUrl":"10.3390/cancers17061013","url":null,"abstract":"<p><p>Asia comprises 60% of the global male population, yet Asian men's health issues, such as prostate cancer, remain sparse in the literature. Clinical researchers have often overlooked prostate cancer in Asian men, as available statistics suggest that Asian men are less likely to develop prostate cancer compared to Caucasian, Black, and Hispanic males. However, cultural investigations have indicated these figures may be influenced by factors such as cultural taboos, superstition and misconception, limited access to diagnostic tools and healthcare facilities, and epidemiological factors in terms of lifestyle, environmental exposure, and genetics. In particular, the lack of diagnostic resources, coupled with cultural stigmas surrounding cancers affecting the genitalia in Asian societies, may contribute to significant underreporting. Rapid aging population growth in East Asia and the continuing shift in Asiatic lifestyles towards Westernization will likely contribute to a continued rise in prostate cancer incidence among Asian men in the coming years. A comprehensive review of novel and commercially available prostate cancer detection tests demonstrates that accurate, less-invasive tools could relieve many of the pressures surrounding Asian men and their prostate health.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Head and Neck Cancer with Prior Allergic Rhinitis.","authors":"Shih-Han Hung, Tzong-Hann Yang, Herng-Ching Lin, Chin-Shyan Chen","doi":"10.3390/cancers17061000","DOIUrl":"10.3390/cancers17061000","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Chronic inflammation has been implicated in cancer development, but the association between allergic rhinitis (AR) and head and neck cancer (HNC) remains unclear. This study aims to investigate this potential relationship using a population-based dataset. <b>Methods</b>: Utilizing the Taiwan Longitudinal Health Insurance Database 2010, we conducted a case-control study encompassing 14,913 HNC patients and 59,652 propensity-score matched controls. Multivariate logistic regression analyses were performed to quantitatively evaluate the association between HNC and prior AR, adjusting for demographic factors and medical comorbidities such as hyperlipidemia, diabetes, hypertension, tobacco use disorder, HPV infection, and alcohol-related disorders. <b>Results</b>: This study identified that 20.19% of the entire cohort had a prior diagnosis of AR, with a significantly higher prevalence in HNC patients relative to controls (26.2% vs. 18.70%). The adjusted odds ratio (OR) for previous AR in HNC patients was 1.559 (95% CI = 1.494-1.627). Furthermore, site-specific analysis revealed increased odds ratios for AR among patients with cancers of the larynx (OR = 1.537, 95% CI = 1.307-1.807), hypopharynx (OR = 1.220, 95% CI = 1.035-1.437), nasopharynx (OR = 2.933, 95% CI = 2.722-3.160), sinonasal (OR = 3.100, 95% CI = 2.424-3.964), salivary glands (OR = 1.470, 95% CI = 1.158-1.865), and thyroid (OR = 1.566, 95% CI = 1.447-1.693). <b>Conclusions</b>: The findings robustly support a significant link between AR and an elevated risk of developing HNC, notably affecting the nasopharynx, sinonasal cavities, larynx, salivary glands, and thyroid.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational Advances in Oncogene and Tumor-Suppressor Gene Research.","authors":"Radoslav Stojchevski, Edward Agus Sutanto, Rinni Sutanto, Nikola Hadzi-Petrushev, Mitko Mladenov, Sajal Raj Singh, Jitendra Kumar Sinha, Shampa Ghosh, Bhuvaneshwar Yarlagadda, Krishna Kumar Singh, Prashant Verma, Sonali Sengupta, Rakesh Bhaskar, Dimiter Avtanski","doi":"10.3390/cancers17061008","DOIUrl":"10.3390/cancers17061008","url":null,"abstract":"<p><p>Cancer, characterized by the uncontrolled proliferation of cells, is one of the leading causes of death globally, with approximately one in five people developing the disease in their lifetime. While many driver genes were identified decades ago, and most cancers can be classified based on morphology and progression, there is still a significant gap in knowledge about genetic aberrations and nuclear DNA damage. The study of two critical groups of genes-tumor suppressors, which inhibit proliferation and promote apoptosis, and oncogenes, which regulate proliferation and survival-can help to understand the genomic causes behind tumorigenesis, leading to more personalized approaches to diagnosis and treatment. Aberration of tumor suppressors, which undergo two-hit and loss-of-function mutations, and oncogenes, activated forms of proto-oncogenes that experience one-hit and gain-of-function mutations, are responsible for the dysregulation of key signaling pathways that regulate cell division, such as p53, Rb, Ras/Raf/ERK/MAPK, PI3K/AKT, and Wnt/β-catenin. Modern breakthroughs in genomics research, like next-generation sequencing, have provided efficient strategies for mapping unique genomic changes that contribute to tumor heterogeneity. Novel therapeutic approaches have enabled personalized medicine, helping address genetic variability in tumor suppressors and oncogenes. This comprehensive review examines the molecular mechanisms behind tumor-suppressor genes and oncogenes, the key signaling pathways they regulate, epigenetic modifications, tumor heterogeneity, and the drug resistance mechanisms that drive carcinogenesis. Moreover, the review explores the clinical application of sequencing techniques, multiomics, diagnostic procedures, pharmacogenomics, and personalized treatment and prevention options, discussing future directions for emerging technologies.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Axillary Burden on Survival: A Comparative Study of Invasive Lobular Carcinoma and Invasive Ductal Carcinoma in Early-Stage Breast Cancer.","authors":"Kwang Hyun Yoon, Jee Hyun Ahn, Jee Ye Kim, Hyung Seok Park, Seung Il Kim, Seho Park","doi":"10.3390/cancers17061002","DOIUrl":"10.3390/cancers17061002","url":null,"abstract":"<p><strong>Purpose: </strong>Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most common breast cancer types. While they differ biologically and pathologically, their association with axillary lymph node (ALN) metastasis and survival remains unclear. This study compares the clinical features of ILC and IDC to evaluate ALN surgery considerations for ILC patients.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed 3543 patients who underwent upfront surgery for early breast cancer at Yonsei University Severance Hospital between January 2015 and December 2019. Multivariate logistic regression assessed factors linked to ALN metastasis, while Cox regression identified predictors of recurrence and survival.</p><p><strong>Results: </strong>Among the patients, 92.1% had IDC and 7.9% had ILC. T2-stage tumors were more prevalent in ILC (31.4% vs. 18.1%, <i>p</i> < 0.001). The rates of ALN metastasis were similar between the groups (IDC: 21.1%, ILC: 24.6%, <i>p</i> = 0.655); however, the presence of more than two metastatic ALNs was more frequent in ILC (9.6% vs. 5.0%, <i>p</i> = 0.004). Factors associated with having >2 metastatic ALNs included histology, suspicious axillary ultrasound, T stage, and lymphovascular invasion. The median follow-up period was 65 months, with no significant differences observed in 8-year recurrence-free survival (ILC: 95.2%, IDC: 94.1%, <i>p</i> = 0.134) or 5-year overall survival (ILC: 97.1%, IDC: 97.4%, <i>p</i> = 0.289).</p><p><strong>Conclusions: </strong>ILC features larger tumors and a higher nodal burden but has similar survival rates to IDC with proper treatment. Caution is essential in axillary surgery to avoid underestimating the nodal burden.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143727979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Diagnostic Accuracy and Complication Rate of Transperineal Versus Transrectal Prostate Biopsy in Prostate Cancer Diagnosis.","authors":"Salam Najjar, Cristian Mirvald, Alexandru Danilov, Apostolos Labanaris, Adrian George Vlaicu, Leonardo Giurca, Ioanel Sinescu, Cristian Surcel","doi":"10.3390/cancers17061006","DOIUrl":"10.3390/cancers17061006","url":null,"abstract":"<p><strong>Introduction: </strong>Transperineal prostate (TP) biopsy has emerged as a substantial alternative to the conventional transrectal (TR) approach for prostate sampling by its ability to sample specific areas of the prostate more effectively. The objective of this review is to conduct a comparative analysis of the current literature regarding diagnostic accuracy, complication rate and clinical outcome of transrectal vs. transperineal approaches in prostate biopsy-naïve patients and in repeated biopsy scenarios.</p><p><strong>Materials and methods: </strong>An extensive search of the literature in PubMed, Scopus, and Web of Science was conducted between September 2010 and September 2024. We utilized a robust and comprehensive retrieval strategy including phrasing the two approaches as follows: (perineal or transperineal) and (rectal or transrectal).</p><p><strong>Conclusions: </strong>The transperineal and transrectal approaches show similar results in the detection of PCa in biopsy-naïve men, similar rates of infection, urinary retention and effectiveness managing biopsy-associated pain. However, in the rebiopsy scenario, the TP approach has demonstrated increased accuracy compared to the TR approach. This has significant implications in decision making and patient counselling.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients with Colorectal Cancer and <i>BRAF^V600E</i>-Mutation in Argentina: A Real-World Study-The EMOGI-CRC01 Study.","authors":"Greta Catani, Stefano Kim, Federico Waisberg, Diego Enrico, Romina Luca, Federico Esteso, Luisina Bruno, Andrés Rodríguez, Marcos Bortz, Berenice Freile, Matías Chacón, Ana Isabel Oviedo Albor, Guillermo Méndez, Ezequiel Slutsky, María Cristina Baiud, Romina Llanos, Ayelen Solonyezny, Luis Basbus, Gerardo Arroyo, Julieta Grasselli, Rosario Pasquinelli, Luciana Bella Quero, María Victoria Faura, Ana Cecilia Adur, Mariano Dioca, Mercedes Tamburelli, Javier Castillo, Juan Manuel O'Connor","doi":"10.3390/cancers17061007","DOIUrl":"10.3390/cancers17061007","url":null,"abstract":"<p><strong>Background/objectives: </strong>The <i>BRAF</i>-mutation is a poor prognostic factor in colorectal cancer (CRC). There is a need for real-world data in low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression-free survival (PFS) and in the first- and second-line setting and sequences of treatment regimens.</p><p><strong>Methods: </strong>We retrospectively analyze patients from ten oncology centers in Argentina, diagnosed with <i>BRAF^V600E</i>-mutated advanced CRC between January 2014 and July 2023.</p><p><strong>Results: </strong>A total of 161 patients with metastatic CRC and <i>BRAF^V600E</i>-mutation. The median age was 58.5 (IQR 47-69), and 21.7% were MMR-deficient (dMMR). Of these patients, 93.8% received first-line treatment. With a median follow-up of 23 months (95% CI 16.5-33.4 months), the median PFS was 9 months (95% CI 7.4-10.5 months). The most common regimen in first line setting was doublet chemotherapy plus anti-VEGF for 49% of the patients. Twenty-six percent of the patients received BRAF inhibitors in the second-line setting, with a median PFS of 5.2 months (95% CI 4.9-NR); the overall response rate (ORR) was 10.5%.</p><p><strong>Conclusions: </strong>This study represents, to the best of our knowledge, the largest published real-world cohort of <i>BRAF^V600E</i>-mutated CRC in Latin America. The heterogeneity of the treatments reflects the existence of barriers to access to high-cost drugs in our country. Cooperative efforts are needed to understand the particular characteristics of this subgroup of patients.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}